

ACTEMRA (TOCILIZUMAB) INFORMED CONSENT FORM

Your physician has recommended an ACTEMRA infusion for the treatment. Before agreeing to this treatment, it is important that you read and understand the following explanation of the ACTEMRA infusion process. This statement will describe the procedure, benefits, discomforts, risks and precautions.

ACTEMRA is a medication that keeps the immune system from attacking healthy tissues in the body. The immune system also defends the body against infections caused by bacteria and viruses. ACTEMRA interferes with an important step in this attack. By decreasing the immune system's attack on normal tissues, ACTEMRA can reduce pain and joint inflammation, and can slow the damage to your bones and cartilage.

Indications

The United States Food and Drug Administration (FDA) has approved ACTEMRA® for the treatment of active Rheumatoid Arthritis. This medication can help control the activity of cells in the immune system that are responsible for the signs and symptoms of Rheumatoid Arthritis.

Dosage and Administration

You will receive your first dose of ACTEMRA followed by additional doses every 4 weeks. Ask your doctor if you miss an infusion when to schedule your next dose.

Potential Adverse Reactions

ACTEMRA is generally well tolerated and most reported reactions are mild to moderate, transient and manageable. The following adverse reactions are the most commonly reported:

- Upper respiratory infection
- Viral infection
- Bronchitis
- Hypertension
- Rash

Some more severe side effects have been reported including:

- Serious infection
- Allergic reactions. These reactions are usually mild or moderate, but can be severe.
- There have been rare cases of certain kinds of cancer in patients receiving ACTEMRA. The role of ACTEMRA in the development of cancer is not known.
- Some patients in studies developed perforations (or holes) in their intestines while on this drug.
 These complications were more common in patients that had GI problems such as Diverticulitis



or other inflammatory bowel diseases that were having procedures done. Talk to your doctor if you have a history of diverticulitis or a history of bowel perforations.

Prior to using ACT	EMRA, please tell your physician or	nurse if you (please initial):
На	ave had any allergic reaction to any	other interleukin-6 inhibitor such as Kevzara
На	ave been previously exposed to tub	erculosis (TB)
На	ave has Hepatitis B or C Infection	
Pr	egnant or breast feeding	
На	ave new symptoms or medical prob	lems
po	•	tly (These include measles, mumps, rubella, oral not live), oral typhoid (typhoid injection is not live)
На	ave ever been diagnosed with Diver	ticulitis or have a history of GI problems
Ar	ny Fever or Current Signs/Symptom	s of an Infection
Ar	ny Acute Cut, Wound or Rash	
•	ossible side effects from this medica n becomes available I will be notific	ation may not have been completely identified and ed.
	portunity to fully read, understand a signing this consent, I am agreeing	and discuss this consent form with my physician to treatment with ACTEMRA.
Patient's Name		Witness' Name
Patient's Signature	2	Witness' Signature
		 Date

